Renal cell carcinoma

Current Problems in Cancer

Volumn 21, Issue 4, 1997, Pages 185-232

  Motzer, Robert J ^b   Nanus, David M ^a   Russo, Paul ^a   Berg, William J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER INVASION; CANCER STAGING; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; NEPHRECTOMY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHRECTOMY; PROGNOSIS; RISK FACTORS;

EID: 0031183028     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0147-0272(97)80007-4     Document Type: Article

References (254)

1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335:865-75.
2. Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of eighteen major cancers in 1985. IntJ Cancer 1993;54:594-606.
3. Pisani R Parkin DM, Ferlay J. Estimates of the world-wide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993 ;5:891-903.
4. Cancer facts and figures-1996. Atlanta: American Cancer Society; 1996.
5. SEER cancer statistics review: 1973-1990. Bethesda, Maryland: National Cancer Institute, 1993; NIH publication no. 93-2789. p. X11-XI22.
6. McCredie M. Pommer W, McLaughlin JK. et al. International renal cell cancer study. II. Analgesics. Int J Cancer 1995;60:345-9.
7. Linblad R Mellemgaard A, Schlehofer B, et al. International renal cell cancer study. V. Reproductive factors, gynecologic operations and exogenous hormones. Int J Cancer 1995:61:192-8.
8. Mellemgaard A. Bergstrom R, Lindblad R et al. International renal cell cancer study. III. Role of weight, height, physical activity and use of amphetamines. Int J Cancer 1995;60:350-4.
9. Mandel JS, McLaughlin JK. Schlehofer B. et al. International renal-cell cancer study. IV. Occupation. Int J Cancer 1995:61:601-5.
10. WolkA, Gridley G, NiwaS, étal. International renal cell cancer study. VII. Role of diet. IntJ Cancer 1995;65:67-74.
11. McLaughlin JK, Blot WJ, Mandel JS, Schuman LM, Mehl ES, Fraumeni JE A population-based case-control study of renal cell carcinoma. J Natl Cancer Inst 1984;72:274-84.
12. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal-cell carcinoma. J Natl Cancer Inst 1986:77:351-6.
13. McLauglin JK, Lindblad P, Melemgaard A, et al. International renal cell cancer study. I. Tobacco use. Int J Cancer 1995;60:194-8.
14. Wolk A, Lindblad P, Adami H. Nutrition and renal cell cancer. Cancer Causes Control 1996:7:5-18.
15. Ishikawa I, Kovacs G. High incidence of papillary renal cell tumours in patients on chronic hemodialysis. Histopathology 1993;22:135-9.
16. Washecka R, Hanna M. Malignant renal tumors in tuberous sclerosis. Urology 1991;37:340-3.
17. Mellemgaard A, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell
18. carcinoma in Denmark. I. Role of socioeconomic status, tobacco use, beverages, and family history. Cancer Causes Control 1994;5:105-13.
19. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine 1989;68:l-29.
20. Cohen AJ, Li FP, Berg S, et al. Hereditary renal cell carcinoma associated with a chromosomal translocation. N Engl J Med 1979;301:592-5.
21. Pathak S, Strong LC, Ferrell RE, Trindade A. Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells. Science 1982;217:939-41.
22. Kovacs G, Brusa P, De Riese W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int J Cancer 1989;43:422-7.
23. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma. J Urol 1994;151:561-6.
24. Li FP, Decker HJ, Zbar B, et al. Clinical and genetic studies of renal cell carcinomas in a family with a constitutional 3;8 translocation. Genetics of familial renal carcinoma. Ann Intern Med 1993;118:106-10.
25. Cronin RE, Kaehny WD, Miller PD, et al. Renal cell carcinoma: unusual systemic manifestations. Medicine 1976;55:291-311.
26. Ritchie AWS, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983; 10:390-400.
27. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
28. Nseyo UO, Williams PD, Murphy GD. Clinical significance of erythropoietin levels in renal carcinoma. Urology 1986;28:301-6.
29. Gotoh A, Kitazawa S, Mizuno Y, et al. Common expression of parathyroid hormone-related protein and no correlation of calcium level in renal cell carcinomas. Cancer 1993 ;71:2803-6.
30. Stadier WM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not as an independent prognostic indicator. J Natl Cancer Inst 1992;84:1835-6.
31. Boxer RJ, Waisman J, Lieber MM, Mampaso FM, Skinner DG. Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 1978;119:468-71.
32. Dawson NA, Barr CF, Alving BA. Acquired dysfibrinogenemia: paraneoplastic syndrome in renal cell carcinoma. Am J Med 1985;78:682-6.
33. Chang S, Yu D, Sherwood ER, Kozlowski JM, Lee C. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol 1992:147:1147-50.
34. Porena M, Vespasiani G, Rosi P, et al. Incidentally detected renal cell carcinoma: role of ultrasonography. J Clin Ultrasound 1992;20:395-400.
35. Hellsten S, Berge T, Whelin L. Unrecognized renal cell carcinoma. Scand J Urol Nephrol 1981;15:269-72.
36. Konnack JW, Grossman HB. Renal cell carcinoma as an incidental finding. J Urol 1985:134:1094-6.
37. Thompson IM, Peek M. Improvement in survival of patients with renal cell carcinoma-the role of the serendipitously detected tumor. J Urol 1988;140:487-90.
38. Smith SJ, Bosniak MA, Megibow AJ, Hulnick DH, Horii SC, Raghavendra BN. Renal cell carcinoma: earlier discovery and increased detection. Radiology 1989;170:699-703.
39. Tsukamoto T, Kumamoto Y, Yamazaki K, et al. Clinical analysis of incidentally found renal carcinomas. Eur Urol 1991;19:I09-13.
40. Aso Y, Homma Y. A survey on incidental renal cell carcinoma in Japan. J Urol 1992;147:340-4.
41. Kassier O, Mukamel E, Hader H, et al. The impact of the improved diagnosis of renal cell carcinoma on the course of the disease. J Surg Oncol 1994;57:201-5.
42. Thoenes W, Storkel S. Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histomorphological elements and their use for diagnostics. Pathol Res Pract 1986;! 81:125-43.
43. van den Berg E, van der Hout AH, Oosterhuis JW, et al. Cytogenetic analysis of epithelial renal-cell tumors: relationship with a new histopathological classification. Int J Cancer 1993;55:223-7.
44. Weiss LM, Gelb AB, Medeiros LJ. Adult renal epithelial neoplasms. Am J Clin Pathol 1995;103:624-35.
45. Storkel S, Steart PV, Drenckhalm D, Thoenes W. The human chromophobe renal cell carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol 1989;56:237-45.
46. Akhtar M, Kardar H, Linjawi T, et al. Chromophobe cell carcinoma of the kidney-a clinicopathologic study of 21 cases. Am J Surg Pathol 1995;19:1245-56.
47. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes l, 2, 6, 10, 13,17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994;145:356-64.
48. Storkel S, Vanderberg E. Morphological classification of renal cancer. World J Urol 1995;13:153-8.
49. Furhmann SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-63.
50. Ro JY, Ayala AG, Sella A, Samuels ML, Swanson DA. Sarcomatoid renal cell carcinoma: a clinicopathologic study of 42 cases. Cancer 1987;59:516-26.
51. Presti JC Jr, Rao PH, Chen Q, et al. Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 1991;51:1544-52.
52. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologie, and pathologic study of 34 cases. Cancer 1976;38:2469-80.
53. Kovacs G, Wilkens L, PappT, De Riese W. Differentiation between papillary and nonpapillary renal cell carcinomas by DNA analysis. J Natl Cancer Inst I989;7:527-30.
54. Kovacs G, Guzesi L, Emanuel A, Kung H. Cytogenetics of papillary renal cell tumors. Genes Chromosom Cancer 1991;3:249-55.
55. Sene AP, Hunt L, McMahon RF, Carroll RN. Renal cell carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br J Urol 1992;70:125-34.
56. Bander NH, Finstad CL, Cordon-Cardo C, Ramsawak RD, Vaughan ED, Whitmore WF. Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets of renal cell carcinomas. Cancer Res 1989;49:6774-80.
57. Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinoma. Genes Chromosom Cancer 1992;4:267-8.
58. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma-clinicopathologic features of 50 cases. J Urol 1995; 154:964-7.
59. Morra MN, Das S. Renal oncocytoma: a review of histogenesis, histopathology, diagnosis and treatment. J Urol 1993; 150:295-302.
60. Kennedy SM, Merino MJ, Linehan WM, Robert JR, Robertson CN, Neumann RD. Collecting duct carcinoma of the kidney. Hum Pathol 1990;21:449-56.
61. Warshauer DM, McCarthy SM, Street L. et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US and CT. Radiology 1988;169:363-5.
62. Amendola MA, Bree BL, Pollack HM, et al. Small renal cell carcinomas: resolving a diagnostic dilemma. Radiology 1988; 166:637-41.
63. Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology 1991;180:85-9.
64. Bosniak MA. The small (<3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology 1991;179:307-17.
65. Bosniak MA. The current radiological approach to renal cysts. Radiology 1986; 158:1 -10.
66. Johnson CD, Dunnick NR, Cohan RH, et al. Renal adenocarcinoma: CT staging of 100 tumors. Am J Roentgenol 1987;148:59-63.
67. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990;144:243-5.
68. Semelka RC, Shoenut JP, Magro CM, Koreker MA, MacMahon R, Greenberg HM. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhancing fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993;3:597-602.
69. Lim DJ, Carter MR Computerized tomography in the preoperative staging for pulmonary metastases in patients with renal cell carcinoma. J Urol 1993;150:1112-4.
70. Newhouse JH. The radiologie evaluation of the patient with renal cancer. Urol Clin North Am 1993;20:231-46.
71. Handbook for staging of cancer. Philadelphia: JB Lippincott; 1993.
72. Robson CJ, Churchill BM, Andersen W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
73. American Cancer Society. Results in treating cancer. Report no. 12, Kidney cancer. Chicago: American Cancer Society; 1989.
74. Couillard DR, DeVere White RW. Surgery of renal cell carcinoma. Urol Clin North Am 1993;20:263-75.
75. Thrasher JB, Paulson DF. Prognostic factors in renal cancer. Urol Clin North Am 1993;20:247-61.
76. Boxer RJ, Waisman J, Lieber MM, Mampaso FM, Skinner DG. Renal carcinoma: computer analysis of 96 patients treated by nephrectomy. J Urol 1979;122:598-601.
77. Selli C, Hinshaw WM, Woodard BH, et al. Stratification of risk factors in renal cell carcinoma. Cancer 1983;52:899-903.
78. Libertino JA, Zinman L, Watkins E. Long-term results of resection of renal cell carcinoma with extension into the inferior vena cava. J Urol 1987;137:21-4.
79. Hatcher PA, Anderson EE, Paulson DF, Carson CC, Robertson JE. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991; 145:20-3.
80. Swierewski DJ, Swierewski MJ, Libertino JA. Radical nephrectomy in patients with renal cell carcinoma with venous, venal caval, and atrial extension. Am J Surg 1994;168:205-9.
81. Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 1990; 143:468-74.
82. Phillips PE, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 1993;41:9-15.
83. Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional lymph nodes in the therapy of renal cell carcinoma. J Urol 1991; 146:1224-7.
84. Ditonno P, Traficante A, Battaglia M, et al. Role of lymphadenectomy in renal cell carcinoma. Prog Clin Biol Res 1992;378:169-74.
85. Sagalowsky AI, Kadesky KT, Ewalt DM, Kennedy TJ. Factors influencing adrenal metastasis in renal cell carcinoma. J Urol 1994; 151:1181-4.
86. Shalev M, Cipolla B, Guille F, Staerman F, Lobel B. Is ipsilateral adrenalectomy a necessary component of radical nephrectomy? J Urol 1995;153:1415-7.
87. Gill IS, McClennan BL, Kerbl K, Carbone JM, Wick M, Clayman RV. Adrenal involvement from renal cell carcinoma: predictive value of computerized tomography. J Urol 1994;152:1082-5.
88. Morgan WR, Zincke H. Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup. J Urol 1990;144:852-8.
89. Moll V, Becht E, Ziegler M. Kidney preserving surgery in renal cell tumors: indications, techniques and results in 152 patients. J Urol 1993;150:319-23.
90. Steinbach F, Stöckle M, Muller SC, et al. Conservative surgery of renal cell tumors in 140 patients: 21 years of experience. J Urol 1992; 148:24-9.
91. Licht MR, Novick AC, Goormastic M. Nephron sparing surgery in incidental versus suspected renal cell carcinoma. J Urol 1994; 152:39-42.
92. Thrasher JB, Robertson JE, Paulson DF. Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 1994;43:160-8.
93. Novick AC, Streem SB, Montie JE, et al. Conservative surgery of renal cell carcinoma: a single-center experience with 100 patients. J Urol 1989;141:835-9.
94. Marberger M, Pugh RCB, Auvert J, et al. Conservation surgery of renal cell carcinoma: the EIRSS experience. Br J Urol 1981;53:528-32.
95. Steinbach F, Stöckle M, Hohenfellner R. Current controversies in nephron-sparing surgery for renal-cell carcinoma. World J Urol 1995;13:163-5.
96. Provet J, Tessler A, Brown J, Golimbu M, Bosniak M, Morales P. Partial nephrectomy for renal cell carcinomas: indications, results and implications. J Urol 1991; 145:472-6.
97. Whang M, O'Toole K, Bixon R, et al. Incidence of multifocal renal cell carcinoma in patients who are candidates for partial nephrectomy. J Urol 1995; 154:968-71.
98. Herr HW. Partial nephrectomy for renal cell carcinoma with a normal opposite kidney. Cancer 1994:73:160-2.
99. Saitoh H, Nakayama M, Nakamura K, Satoh T. Distant metastasis of renal adenocarcinoma in nephrectomized cases. J Urol 1982;127:1092-5.
100. Cherrie RJ, Goldman DG, Lindner A, deKernion JB. Prognostic implications of vena caval extension of renal cell carcinoma. J Urol 1982;128:910-2.
101. Marshall F, Dietrick DD, Baumgartner WA, Reitz BA. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol 1988;139:1166-72.
102. Novick A. Current surgical approaches, nephron-sparing surgery, and the role of surgery in the integrated immunologie approach to renal-cell carcinoma. Semin Oncol 1995:22:29-33.
103. McCaffrey JA, Motzer RJ. What is the role of nephrectomy in patients with metastatic renal cell carcinoma? Semin Oncol 1996;23:xix-xx.
104. Robertson CN, Linehan WM, Pass HI, et al. Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 1990; 144:6148.
105. Rackley RR, Klein EA, Novick AD. Morbidity and mortality of primary adjuvant nephrectomy in immunotherapy for renal cell carcinoma. J Urol 1991;145:422A.
106. Rafla S. Renal cell carcinoma: natural history and results of treatment. Cancer 1970;25:26-40.
107. Parienty RA, Richard F, Pradel J, et al. Local recurrence after nephrectomy for primary renal cancer. CT recognition. J Urol 1984:13:246-9.
108. Campbell SC, Novick AC. Management of local recurrence following radical nephrectomy or partial nephrectomy. Urol Clin North Am 1994:21:593-9.
109. Dineen MK, Pasture RD, Emrich LJ. Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 1988:140:277-9.
110. Golimbu M, Joshi P, Sperber A. Renal cell carcinoma: survival and prognostic factors. Urology 1991;27:291-301.
111. Klugo RC, Detmers M, Stiles RE. Aggressive versus conservative treatment of stage IV renal cell carcinoma. J Urol 1977:118:244-6.
112. Maldazys JD, deKernion JB. Prognostic factors in renal cell carcinoma. J Urol 1986; 136:376-9.
113. Middleton RG. Surgery for metastatic renal cell carcinoma. J Urol 1967;97:973.
114. Wagle DG, Seal DR. Renal cell carcinoma: a review. J Surg Oncol 1970;2:23.
115. Ruiz JL, Vera C, Server G, et al. Renal cell carcinoma: late recurrences in 2 cases. Eur Urol 1991;20:167-9.
116. Rackley R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D. The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma. J Urol 1994;152:1399-403.
117. Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995;154:28-31.
118. Rabinovitch RA, Zelefsky MJ, Gaynor JJ, Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J Clin Oncol 1994;12:206-12.
119. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiât Oncol Biol Phys 1987;13:665-72.
120. Trump DL, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma [abstract]. Proc ASCO 1996;15:253.
121. Jacqmin D, Saussine C, Roca D, et al. Multiple tumors in the same kidney: incidence and therapeutic implications. Eur Urol 1992;21:32-4.
122. Lee SE, Kim HH. Validity of kidney-preserving surgery for localized renal cell carcinoma. Eur Urol 1994;25:204-8.
123. Gilbert BR, Russo P, Zirinsky K, Kazam E, Fair WR, Vaughan ED. Intraoperative sonography: application in renal cell carcinoma. J Urol 1988;139:582-4.
124. Assimos DG, Boyce H, Woodruff RD, Harrison LH, McCullough DL, Kroovand RL. Intraoperative renal ultrasonography: a useful adjunct to partial nephrectomy. J Urol 1991; 146:1218-20.
125. Wirth MR Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;20:283-95.
126. Motzer RJ, Vogelzang NJ. Chemotherapy for renal cell carcinoma. In: Raghaven D, Scher HI, Leibel SA, et al., eds. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven; 1997. p. 885-96.
127. Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977;9:277-88.
128. Hrushesky WJ, von Roemeling R. Lanning RM, Rabatin JT. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990;8:1504-13.
129. Damascelli B, Marchiano A, Spreafico C, et al. Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 1990;66:237-41.
130. Merrouche Y, Négrier S, Lanier F. Phase II study of continuous circadian infusion FUDR in metastatic renal cell cancer (RCC). Eur J Cancer Clin Oncol 1991;27:S102.
131. Dexeus FH, Logothetis CJ, Sella A, et al. Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 1991;146:709-13.
132. Budd GT, Murthy S, Klein E, et al. Time-modified infusion of floxuridine in metastatic renal cell carcinoma (mRCC) [abstract]. Proc AACR 1992:33:220.
133. Conroy T, Geoffrois L, Guillemin F, et al. Simplified chronomodulated continuous infusion of floxuridine in patients with metastatic renal cell carcinoma. Cancer 1993;72:2190-7.
134. Porter RL, Bakker PJM, Kurth KH. Circadian modulated continuous infusion of FUDR in patients with disseminated renal cell cancer (RCC). Eur J Cancer 1993;29:116.
135. Bjarnason GA, Hrushesky WJM, Diasio R, et al. Rat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer (RCC): a phase III study (abstract]. Proc ASCO 1994; 13:233.
136. Bloom HJ. Hormone treatment of renal tumours: experimental and clinical observations. In: Riches E, ed. Tumours of the kidney and ureter. Edinburgh and London: ES Livingstone; 1964. p. 311-38.
137. Bloom HJ. Hormone-induced and spontaneous regression of metastatic renal cancer. Cancer 1973;32:1066-71.
138. Pearson J, Friedman MA, Hoffman PG Jr. Hormone receptors in renal cell carcinoma. Their utility as predictors of response to endocrine therapy. Cancer Chemother Pharmacol 1981;6:151-4.
139. Nakano E, Tada Y, Fujioka H, et al. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J Urol 1984;132:240-5.
140. Gottesman JE. Crawford ED. Grossman HB, Scardino P, McCracken JD. Infarctionnephrectomy for metastatic renal carcinoma. Urology 1985;25:248-50.
141. Samuels ML, Sullivan P, Howe CD. Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma). Cancer 1968:22:525-32.
142. Morales A, Kiruluta G, Lott S. Hormones in the treatment of metastatic renal cancer. J Urol 1975;114:692-3.
143. Alberto P, Senn HJ. Hormonal therapy of renal carcinoma alone and in association with cytostatic drugs. Cancer 1974;33:1226-9.
144. Schomburg A, Kirchner H, Fenner M, Menzel T, Poliwoda H, Atzpodien J. Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur J Cancer 1993;29A:737-40.
145. Papac RJ, Keohane MF. Hormonal therapy for metastatic renal cell carcinoma: combined androgen and Provera followed by high dose tamoxifen. Eur J Cancer 1993;29A:997-9.
146. Feun LG, Drelichman A, SinghakowintaA, VaitkeviciusVK, Oishi N. Phase II study of nafoxidine in the therapy for advanced renal carcinoma. Cancer Treat Rep 1979;63:149-50.
147. Stolbach LL, Begg CB, Hall T, Horton J. Treatment of renal carcinoma: a phase III randomized trial of oral medroxyprogesterone (Provera), hydroxyurea, and nafoxidine. Cancer Treat Rep 1981;65:689-92.
148. Schornagel JH, Verweij T, ten Bokkel Huinink WW. Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma. J Urol 1989;142:253-6.
149. WadaT, HoujouT, KuboR,Yasutomi M, KuritaT. A combined chemo-endocrine treatment with tegafur, Adriamycin, methotrexate and tamoxifen for advanced renal cell carcinoma. Anticancer Res 1993;13:2465-7.
150. Hahn RG, Temkin NR, Savlov ED, et al. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Cancer Treat Rep I978;62:1093-5.
151. Katakkar SB, Franks CR. Chemo-hormonal therapy for metastatic renal cell carcinoma with Adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate. Cancer Treat Rep 1978:62:1379-80.
152. Vosika GJ, Ryan MJ, Fortuny IA, et al. CCNU, vinblastine, and Delalutin therapy in renal cell carcinoma. Med Pediatr Oncol 1978;5:89-91.
153. Porzsolt F, Messerer D, Hautmann R, et al. Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial. J Cancer Res Clin Oncol 1988:114:95-100.
154. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
155. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-87.
156. Rodenburg CJ, Nooter K, Herweijer H. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991;2:305-6.
157. Murphy BR, Rynard SM, Pennington KL, Grosh W, Loehrer PJ. A phase U trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. A Hoosier Oncology Group Study. Am J Clin Oncol 1994;17:10-3.
158. Schwartsmann G, Medina de Cunha F, Silveira LA, et al. Phase II trial of vinblastine plus nifedipine (VN) in patients with advanced renal cell carcinoma (RCC). Brazilian Oncology Trials Group [letter]. Ann Oncol 1991;2:443.
159. Agarwala S, Bahnson R, Wilson J, Szumowski J, Downs M, Ernstoff M. Evaluation of the combination of vinblastine and quinidine in patients with metastatic renal cell carcinoma [abstract]. Proc AACR 1991;32:195.
160. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995; 13:1958-65.
161. Samuels BL, Trump DL, Rosner G, Vogelzang NJ, Schilsky RL. Multidrug resistance modulator in renal cell carcinoma using cyclosporin-A or tamoxifen [abstract]. Proc ASCO 1994; 13:252.
162. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981:41:1967-72.
163. Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and Adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7.
164. Gore ME, Selby PJ, Millar B, Maitland J, McElwain TJ. The use of verapamil to overcome drug resistance in myeloma [abstract]. Proc ASCO 1988;7:228.
165. Dalton WS, Grogan TM, Meltzer PS, et al. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
166. Presant CA, Kennedy PS, Wiseman C, et al. Verapamil reversal of clinical doxorubicin resistance in human cancer. Am J Clin Oncol 1986;9:355-7.
167. Benson AB, Trump DL, Koeller JM, et al. Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 1985;69:795-9.
168. Cairo MS, Siegel S, Anas N, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pédiatrie tumors. Cancer Res 1989;49:1063-6.
169. Echizen H, Brecht T, Niedergesass S, Vogelgesang B, Eichelbaum M. The effect of dextro-, leva-, and racemic verapamil on atrioventricular conduction in humans. Am HeartJ 1985:109:210-7.
170. Mickisch GH, Kossig J, Keilhauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990;50:3670-4.
171. Gruber A, Peterson C, Reizenstein P. D-Verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 1988;41:224-6.
172. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993;11:1629-35.
173. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alphainterferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128-31.
174. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary métastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
175. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP. Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 1990;50:4190-4.
176. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993;11:1368-75.
177. Fossa SD, Martinelli G, Otto U, et al. Recombinant Interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase 111 study. Ann Oncol 1992;3:301-5.
178. Neidhart JA, Anderson SA, Harris JE, et al. Vinblastine fails to improve response of renal cancer to interferon alfa-n 1 : high response rate in patients with pulmonary mé tastases. J Clin Oncol 1991;9:832-6.
179. Krown SE. Interferon treatment of renal cell carcinoma: current status and future prospects. Cancer 1987:59:647-51.
180. Rosenberg SA, Lotze MT, Muul LA, et al. A progress report of the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin2 or high-dose interleukin-2 alone. N Engl J Med 1987:316:889-97.
181. Murray Law T. Motzer RJ, Mazumdar M, et al. Phase III randomized trial of interleukin2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 1995:76:824-32.
182. Fyfe G, Fisher SA, Sznol M, Parkinson DR, Louie A. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995:13:688-96.
183. Ilson DH, Motzer RJ, Kradin RL, et al. A phase II trial of interleukin-2 and interferon alfa2a in patients with advanced renal cell carcinoma. J Clin Oncol 1992; 10:1124-30.
184. Fossa SD, Raabe N, Moe B. Recombinant interferon-alpha with or without vinblastine in metastatic renal carcinoma. Results of a randomised phase II study. Br J Urol 1989:64:468-71.
185. Atkins MB, Sparano J, Fisher RJ, et al. Randomized phase II trial of high-dose interleukin2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol 1993:11:661-70.
186. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993;11:1809-16.
187. Négrier S, Escudier B, Lasset C, et al. The FNCLCC CRECY trial: interleukin-2 (IL-2) + interferon (IFN) is optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC)(abstract]. Proc ASCO 1996:15:248.
188. Hanninen EJ, Kirchner H, Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive patients. J Urol 1996; 155:19-25.
189. Motzer RJ, Schwartz L, Murray Law T, et al. Interferon alfa-2a and 13-cw-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995:13:1950-7.
190. Pierce WC, Belldegrun A, Figlin RA. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. Semin Oncol 1995;22:7480.
191. Osband ME. Lavin PT, Babayan RK, et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 1990:335:994-8.
192. Cordon-Cardo C, Finstad CL, Bander NH, et al. Immuno-anatomic distribution of cytostructural and tissue-associated antigens of the human urinary tract. Am J Pathol 1987:126:269-84.
193. Nanus DM, Engelstein D, Gastl GA, et al. Molecular cloning of the human kidney differentiation antigen gp160; human aminopeptidase A. Proc Natl Acad Sei USA 1993;90:7069-73.
194. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 1987;327:721-4.
195. Mäher ER, Yates JRW. Familial renal cell carcinoma: clinical and molecular genetic aspects. Br J Cancer 1991;63:176-9.
196. Seizinger BR, Rouleau GA, Ozelius LJ, et al. von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-9.
197. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
198. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
199. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
200. Chen F, Kishida T, Duh FM, et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995;55:4804-7.
201. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sei USA 1994;91:9700-4.
202. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269:1402-6.
203. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-6.
204. Richards FM, Schofield PN, Fleming S, Mäher ER. Expression of the von HippelLindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996;5:639-44.
205. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. NatMed 1995; 1:822-6.
206. Thrashbingham CA, Salazar H, Freed JJ, Greenberg RE, Tartof KD. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 1995;55:6189-95.
207. Moch H, Presti JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996:56:27-30.
208. Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J Urol 1994; 12:162-8.
209. Vandenberg A, Hulsbeek MMF, Dejong D, et al. Major role for 3p21 region and lack of involvement of the t(3-8) breakpoint region in the development of renal cell carcinoma suggested by loss of heterozygosity analysis. Gene Chromosom Cancer 1996;15:64-72.
210. UchidaT, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K. Infrequent involvement of p53 mutations and loss of he.Oterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol 1993;150:1298-301.
211. Imai Y, Strohmeyer TG, Fleischhacker M, Stamon DJ, Koeffler HP. p53 Mutations and MDM-2 amplification in renal cell cancers. Mod Pathol 1994;7:766.
212. Kikuchi Y, Kishi T, Suzuki M, Furusato M, Aizawa S. Polymerase chain reactionsingle strand conformation polymorphism analysis of the p53 gene in paraffin-embedded surgical material from human renal cell carcinomas. Virchows Arch 1994;424:229-33.
213. Bot FJ, Godschalk JC, Krishnadath KK, van der Kwast TH, Bosnian FT. Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994;57:634-7.
214. Uhlman DL, Nguyen PL, Manivel JC, et al. Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994:86:1470-5.
215. Papandreou CN, Bogenreider T, Loganzo F, Albino AP, Nanus DM. Expression and sequence analysis of the p21 (WAF1/CIP1 ) gene in renal cancers. Urology 1997;49:481 6.
216. Walther MM, Gnarra JR, Elwood L, et al. Loss of heterozygosity occurs centromeric to RB without associated abnormalities in the retinoblastoma gene in tumors from patients with metastatic renal cell carcinoma. J Urol 1995;153:2050-4.
217. Cairns P. Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary renal cell carcinomas. Cancer Res 1995:55:224-7.
218. Nanus DM, Mentle IR, Motzer RJ, Bander NH, Albino AP. Infrequent ras oncogene point mutations in renal cell carcinoma. J Urol 1990; 143:175-8.
219. Oka H, Chatani Y, Hoshino R, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 1995;55:4182-7.
220. Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD, Fair WR. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989:49:3407-11.
221. Uhlman DL, Nguyen P, Manivel JC, et al. Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma-correlation with metastatic behavior and prognosis. Clin Cancer Res 1995; 1:913-20.
222. Atlas 1. Mendelsohn J, Baselga J. Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res 1992:52:3335-9.
223. Kellerer M. Corleta HVE, Muhlhofer A. et al. Insulin- and insulin-like growth-factor-I receptor tyrosine kinase activities in human renal carcinoma. Int J Cancer 1995:62:501 7.
224. Nanus DM. Schmitz-Drager BJ. Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993:85:1597-9.
225. Berger DP, Herbstritt L. Dengler WA, et al. Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Ann Oncol 1995:6:817-25.
226. Fidler U. The biology of renal cancer metastasis. Semin Urol 1992:10:3-11.
227. Yao M, Shuin T. Misaki H, KubotaY. Enhanced expression of c-mvr and epidermal growth factor receptor (C-erbB-1 ) genes in primary human renal cancer. Cancer Res 1988:48:6753-7.
228. Lipponen P. Eskelinen M, Syrjanen K. Expression of tumour-suppressor gene Rb. apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995:71:863-7.
229. Anglard P. Tory K. Brauch H. et al. Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res 1991 ;51:1071 -7.
230. Brooks JD. Bova GS. Marshall FF, Isaacs WB. Tumor suppressor gene allelic loss in human renal cancers. J Urol 1993:150:1278-83.
231. Kanayama H. Takigawa H, Kagawa S. Analysis of nm23 gene expressions in human bladder and renal cancers. Int J Urol 1994; 1:324-31.
232. Walther MM. Anglard P, Gnarra J, et al. Expression of NM23 in cell lines derived from patients with metastatic renal cell carcinoma. J Urol 1995:154:278-82.
233. Suzuki Y. Tamura G. Maesawa C, Fujioka T. Kubo T. Satodate R. Analysis of genetic alterations in renal cell carcinoma using the polymerase chain reaction. Virchows Arch 1994:424:453-7.
234. Shimazui T, Giroldi LA, Bringuier PP, Oosterwijk E, Schalken JA. Complex cadherin expression in renal cell carcinoma. Cancer Res 1996;56:3234-7.
235. Gilcrease MZ, Truong L, Brown KRW. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol 1996;27:1355-60.
236. McLaughlin JK, Chou W, Mandel JS, et al. International renal-cell cancer study. VIE. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995:63:216-21.
237. Hahn DM, Schimpff SC, Ruckdeschel JC, Wiernik PH. Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thiotepa, or bleomycin. Cancer Treat Rep 1977:61:1585-7.
238. Kuebler JP, Hogan TF, Trump DL, Bryan GT. Phase II study of continuous 5-day vinblastine infusion in renal adenocarcinoma. Cancer Treat Rep 1984:68:925-6.
239. Zeffron J, Yagoda A, Kelsen D, Winn R. Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate. Anticancer Res 1984;4:411-4.
240. Tannock IF, Evans WK. Failure of 5-day vinblastine infusion in the treatment of patients with renal cell carcinoma. Cancer Treat Rep 1985:69:227-8.
241. Crivellari D, Tumolo S, Frustaci S, et al. Phase II study of five-day continuous infusion of vinblastine in patients with metastatic renal-cell carcinoma. Am J Clin Oncol 1987:10:231-3.
242. Elson PJ, Kvols LK, Vogl SE, et al. Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma. Invest New Drugs 1988:6:97-103.
243. Fossa SD, Droz JP, Pavone-Macaluso MM, Debruyne FJ, Vermeylen K, Sylvester R. Vinblastine in metastatic renal cell carcinoma: EORTC phase U trial 30882. The EORTC Genitourinary Group. Eur J Cancer 1992;28A:878-80.
244. Richards F III, Cooper MR. Jackson DV, et al. Continuous 5-day (D) intravenous (IV) FUDR infusion for renal cell carcinoma (RCC): a phase I-II trial of the Piedmont Oncology Association [abstract]. Proc ASCO 1991; 10:170.
245. Wilkinson MJ, Frye JW, Small EJ, et al. A phase n study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer 1993:71:3601.
246. Talley RW, Moorhead El, Tucker WG, San Diego EL, Brennan MJ. Treatment of metastatic hypernephroma. J Am Med Assoc 1969;207:322-8.
247. Paine CH, Wright FW, Ellis F. The use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body. Br J Cancer 1970;24:277-82.
248. Bloom HJ. Medroxyprogesterone acetate (Provera) in the treatment of metastatic renal cancer. Br J Cancer 1971;25:250-65.
249. Wagle DG, Murphy GP. Hormonal therapy in advanced renal cell carcinoma. Cancer 1971:28:318-21.
250. Werf-Messing B, Gilse HA. Hormonal treatment of métastases of renal carcinoma. Br J Cancer 1971:25:423-7.
251. Talley RW. Chemotherapy of adenocarcinoma of the kidney. Cancer 1973;32:1062-5.
252. Tirelli U, Frustaci S, Galligioni E, et al. Medical treatment of metastatic renal cell carcinoma. Tumori 1980:66:235-40.
253. Atzpodien J, Kirchner H, Hanninen EL, Decken M, Fermer M, Poliwoda H. Interleukin2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A(suppl 5):S6-8.
254. Sella A, Zukiwski A, Robinson E, et al. Interleukin-2 (IL-2) with interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in patients with metastatic renal cell cancer (RCC) [abstract]. Proc ASCO 1994;13:237.